NO20025375L - Fremgangsmåte for behandling og midler som er nyttige for behandlingen - Google Patents

Fremgangsmåte for behandling og midler som er nyttige for behandlingen

Info

Publication number
NO20025375L
NO20025375L NO20025375A NO20025375A NO20025375L NO 20025375 L NO20025375 L NO 20025375L NO 20025375 A NO20025375 A NO 20025375A NO 20025375 A NO20025375 A NO 20025375A NO 20025375 L NO20025375 L NO 20025375L
Authority
NO
Norway
Prior art keywords
treatment
cancers
agents useful
growth
present
Prior art date
Application number
NO20025375A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025375D0 (no
Inventor
Mathew Vadas
Jennifer Gamble
Pu Xia
Lijun Wang
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of NO20025375D0 publication Critical patent/NO20025375D0/no
Publication of NO20025375L publication Critical patent/NO20025375L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20025375A 2000-05-11 2002-11-08 Fremgangsmåte for behandling og midler som er nyttige for behandlingen NO20025375L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ7447A AUPQ744700A0 (en) 2000-05-11 2000-05-11 A method of treatment and agents useful for same
PCT/AU2001/000539 WO2001085953A1 (fr) 2000-05-11 2001-05-11 Sphingosine kinase et ses utilisations

Publications (2)

Publication Number Publication Date
NO20025375D0 NO20025375D0 (no) 2002-11-08
NO20025375L true NO20025375L (no) 2003-01-07

Family

ID=3821526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025375A NO20025375L (no) 2000-05-11 2002-11-08 Fremgangsmåte for behandling og midler som er nyttige for behandlingen

Country Status (17)

Country Link
US (1) US20040014635A1 (fr)
EP (1) EP1290182B1 (fr)
JP (1) JP2003532423A (fr)
CN (1) CN1436241A (fr)
AT (1) ATE492276T1 (fr)
AU (3) AUPQ744700A0 (fr)
BR (1) BR0110759A (fr)
CA (1) CA2408196A1 (fr)
DE (1) DE60143697D1 (fr)
HK (1) HK1054409A1 (fr)
IL (1) IL152672A0 (fr)
MX (1) MXPA02011112A (fr)
NO (1) NO20025375L (fr)
NZ (1) NZ543272A (fr)
RU (1) RU2326690C2 (fr)
WO (1) WO2001085953A1 (fr)
ZA (1) ZA200209066B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
CA2432978C (fr) 2000-12-22 2012-08-28 Medlyte, Inc. Compositions et procedes destines au traitement et a la prevention de troubles et de maladies cardio-vasculaires, et a l'identification d'agents therapeutiques correspondants
JP4667749B2 (ja) * 2002-01-17 2011-04-13 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド スフィンゴ脂質代謝および／またはシグナル伝達の調節のための組成物および方法
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
WO2003082322A1 (fr) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. Méthode de modulation d'activité cellulaire
US20060205688A1 (en) * 2002-10-14 2006-09-14 Medvet Science Pty. Ltd. Method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase
US20040171037A1 (en) * 2002-11-19 2004-09-02 Jing Li Amplified genes involved in cancer
MXPA06014888A (es) * 2004-06-15 2007-03-21 Medvet Science Pty Ltd Metodos para modular actividad celular que involucra esfingosina cinasa y agentes para los mismos, y variantes de esfingosina cinasa.
EP1812797B1 (fr) * 2004-10-28 2013-03-20 Lpath, Inc. Compositions et methodes permettant de traiter et de prevenir des maladies hyperproliferatives
US8324237B2 (en) * 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
CA2612640A1 (fr) * 2005-06-21 2006-12-28 Medvet Science Pty. Ltd. Modulation de la signalisation de l'egfr par modulation de la signalisation de sphingosine kinase
CA2612644A1 (fr) * 2005-06-21 2006-12-28 Medvet Science Pty. Ltd. Modulation de la signalisation de la sphingosine kinase
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
PL2087002T3 (pl) 2006-10-27 2015-02-27 Lpath Inc Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2019182191A1 (fr) 2018-03-21 2019-09-26 경북대학교 산학협력단 Composition pharmaceutique pour la prévention ou le traitement d'une maladie neurodégénérative comprenant un agent d'acétylation de cox2 en tant que principe actif

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5068175A (en) * 1989-05-26 1991-11-26 Board Of Regents, The University Of Texas Sysem Method of detecting ras oncogene related malignancies
JPH10182627A (ja) * 1996-12-20 1998-07-07 Sankyo Co Ltd 新規化合物Ｓ−１５１８３ａ及びＳ−１５１８３ｂ
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AU4097999A (en) * 1998-05-26 1999-12-13 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
CA2335941C (fr) * 1998-06-29 2011-03-22 Barry James Maurer Traitement de troubles hyperproliferants
EP1192247B9 (fr) * 1999-05-13 2007-10-31 Johnson & Johnson Pharmaceutical Research and Development LLC Enzyme sphingosine kinase
AU1020201A (en) * 1999-10-28 2001-05-08 Warner-Lambert Company Human sphingosine kinase gene
US6830916B2 (en) * 2000-03-02 2004-12-14 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
DK1268509T3 (da) * 2000-04-03 2010-03-08 Daiichi Sankyo Co Ltd Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf
US20060205688A1 (en) * 2002-10-14 2006-09-14 Medvet Science Pty. Ltd. Method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase

Also Published As

Publication number Publication date
CA2408196A1 (fr) 2001-11-15
HK1054409A1 (zh) 2003-11-28
EP1290182B1 (fr) 2010-12-22
NO20025375D0 (no) 2002-11-08
AU2001256001B2 (en) 2007-03-15
AU5600101A (en) 2001-11-20
DE60143697D1 (de) 2011-02-03
ATE492276T1 (de) 2011-01-15
JP2003532423A (ja) 2003-11-05
CN1436241A (zh) 2003-08-13
WO2001085953A1 (fr) 2001-11-15
EP1290182A1 (fr) 2003-03-12
BR0110759A (pt) 2003-05-06
US20040014635A1 (en) 2004-01-22
AUPQ744700A0 (en) 2000-06-01
NZ543272A (en) 2009-04-30
EP1290182A4 (fr) 2006-01-11
IL152672A0 (en) 2003-06-24
MXPA02011112A (es) 2004-08-19
ZA200209066B (en) 2004-04-07
RU2326690C2 (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
NO20025375L (no) Fremgangsmåte for behandling og midler som er nyttige for behandlingen
GB0318438D0 (en) Early entry
GT199900019A (es) Formulas farmaceuticamente estables de solucion de oxaliplatino.
SG148864A1 (en) Methods of treating cancer and related methods
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
YU14701A (sh) Nove hidratne forme natrijum alendronata, procesi njihovog dobijanja i njihov farmaceutski sastav
PT1294747E (pt) Métodos de síntese para aplidina e novos derivados antitumorais e seus métodos de produção e utilização
EP1461313A4 (fr) Inhibiteurs de l'adam-10 humaine
IL150060A0 (en) Novel purines
EP1532131A4 (fr) Composes du type motilide
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
HUP0102967A2 (hu) Eljárás organoszilil-alkilpoliszulfánok előállítására
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
TR200200278T2 (tr) Kalsilitik bileşimler
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
MY139348A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY135359A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
AU2002220712A1 (en) Stem cells, method for expansion in vitro and use thereof
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
MY139443A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
GB9425071D0 (en) Chondrocyte cell lines
MY149837A (en) New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
ATE441332T1 (de) Ozonbehandlung von lignocellulose substraten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application